Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022

Rhizen Pharma announces presentations at AACR showcasing its differentiated clinical stage PARP and DHODH programs Preclinical data on Rhizen's differentiated PARP inhibitor RP12146, indicates

Related Keywords

United States ,Switzerland ,American ,Samyukta Bhagwati ,Kostenloser Wertpapierhandel ,Swaroop Vakkalanka ,Rhizen Pharma ,American Association For Cancer Research ,Rhizen Pharmaceuticals ,Rhizen Pharmaceuticals Ag Contact ,Rhizen Pharmaceuticals Ag ,Corporate Affairs Communications ,Ribose Polymerase ,Dihydro Orotate Dehydrogenase ,American Association ,Cancer Research ,Small Molecule Therapeutic Agents ,Rhizen ,Pharmaceuticals ,Presents ,Data ,Differentiated ,Carp ,Hodh ,Inhibitor ,Programs ,Racr ,022 ,